|
US4234571A
(en)
*
|
1979-06-11 |
1980-11-18 |
Syntex (U.S.A.) Inc. |
Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
|
|
DE3411224A1
(de)
*
|
1984-03-27 |
1985-10-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
|
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
|
US4705778A
(en)
*
|
1985-10-22 |
1987-11-10 |
Sri International |
Orally active LHRH analogs
|
|
JPH0284272U
(da)
*
|
1988-12-20 |
1990-06-29 |
|
|
|
JP2672677B2
(ja)
*
|
1989-02-09 |
1997-11-05 |
タツプ・フアーマシユーテイカルズ・インコーポレイテツド |
Ｌｈｒｈ同族体
|
|
US5372996A
(en)
*
|
1989-03-10 |
1994-12-13 |
Endorecherche, Inc. |
Method of treatment of androgen-related diseases
|
|
PH30747A
(en)
*
|
1989-03-10 |
1997-10-17 |
Endorech Inc |
Combination therapy for the treatment of estrogen sensitive disease.
|
|
EP0485392B1
(en)
*
|
1989-07-07 |
1998-09-09 |
Endorecherche Inc. |
Androgen derivatives for use in the inhibition of sex steroid activity
|
|
CA2062792C
(en)
*
|
1989-07-07 |
2006-03-21 |
Fernard Labrie |
Treatment of androgen-related diseases
|
|
GB9112859D0
(en)
*
|
1991-06-14 |
1991-07-31 |
Ici Plc |
Peptide process
|
|
KR950701527A
(ko)
*
|
1992-05-21 |
1995-04-28 |
라브리 페르낭 |
테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
|
|
US7833543B2
(en)
*
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
|
US6413536B1
(en)
|
1995-06-07 |
2002-07-02 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system and medical or surgical device
|
|
CA2192782C
(en)
|
1995-12-15 |
2008-10-14 |
Nobuyuki Takechi |
Production of microspheres
|
|
CA2192773C
(en)
|
1995-12-15 |
2008-09-23 |
Hiroaki Okada |
Production of sustained-release preparation for injection
|
|
EP1008656A4
(en)
|
1996-06-13 |
2000-09-20 |
Itoham Foods Inc |
METHOD FOR PRODUCING LH-RH DERIVATIVES
|
|
US6051558A
(en)
*
|
1997-05-28 |
2000-04-18 |
Southern Biosystems, Inc. |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
|
US20060025328A1
(en)
*
|
1997-05-28 |
2006-02-02 |
Burns Patrick J |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
|
US6242421B1
(en)
|
1997-11-06 |
2001-06-05 |
Richard Lloyd Bowen |
Methods for preventing and treating Alzheimer's disease
|
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
|
ES2154590B1
(es)
|
1999-05-20 |
2001-11-01 |
Lipotec Sa |
Procedimiento de sintesis de peptidos en fase solida
|
|
AR023940A1
(es)
|
2000-05-03 |
2002-09-04 |
Eriochem Sa |
Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
|
|
DE10032256C2
(de)
*
|
2000-07-03 |
2003-06-05 |
Infineon Technologies Ag |
Chip-ID-Register-Anordnung
|
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
|
LT3351246T
(lt)
|
2001-02-19 |
2019-07-10 |
Novartis Pharma Ag |
Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
|
|
SK14042003A3
(sk)
|
2001-05-16 |
2004-05-04 |
Novartis Ag |
Kombinácia N-{5-[4-metylpiperazinometyl)benzoylamido]-2- metylfenyl}-4-(3-pyridyl)-2-pyrimidínamínu chemoterapeutického činidla a farmaceutický prostriedok, ktorý ju obsahuje
|
|
US20060287282A1
(en)
*
|
2001-06-25 |
2006-12-21 |
Steiner Mitchell S |
Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
|
|
US7812044B2
(en)
|
2001-11-13 |
2010-10-12 |
Takeda Pharmaceutical Company Limited |
Anticancer agents
|
|
GB0128510D0
(en)
*
|
2001-11-28 |
2002-01-23 |
Novartis Ag |
Organic compounds
|
|
US20030144203A1
(en)
*
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
EP1944026B1
(en)
|
2002-05-16 |
2013-06-26 |
Novartis AG |
Use of EDG receptor binding agents in cancer
|
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
|
ATE482695T1
(de)
*
|
2002-12-13 |
2010-10-15 |
Durect Corp |
Orale darreichungsform mit flüssigen hochviskosen trägersystemen
|
|
JP4681548B2
(ja)
|
2003-07-22 |
2011-05-11 |
アステックス・セラピューティクス・リミテッド |
３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用
|
|
GB0320806D0
(en)
*
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
|
SG152225A1
(en)
|
2004-04-07 |
2009-05-29 |
Novartis Ag |
Inhibitors of iap
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
RU2006145886A
(ru)
*
|
2004-06-25 |
2008-06-27 |
Такеда Фармасьютикал Компани Лимитед (Jp) |
Производные метастина и их применение
|
|
LT2767292T
(lt)
*
|
2004-09-17 |
2016-12-12 |
Durect Corporation |
Palaikomosios vietinės anestezijos mišinys su saib
|
|
GB0425854D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Astrazeneca Ab |
Therapeutic treatment
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
MX2007008781A
(es)
|
2005-01-21 |
2007-09-11 |
Astex Therapeutics Ltd |
Compuestos farmaceuticos.
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
ATE452145T1
(de)
|
2005-05-03 |
2010-01-15 |
Novetide Ltd |
Verfahren zur herstellung von peptidderivaten
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
|
WO2007038459A2
(en)
|
2005-09-27 |
2007-04-05 |
Novartis Ag |
Carboxyamine compounds and their use in the treatment of hdac dependent diseases
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
WO2007128820A1
(en)
|
2006-05-09 |
2007-11-15 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
|
DE602007013441D1
(de)
|
2006-09-29 |
2011-05-05 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
DK2117521T3
(da)
|
2006-11-03 |
2012-09-03 |
Durect Corp |
Transdermale indgivelsessystemer omfattende bupivacain
|
|
KR20090110913A
(ko)
|
2007-02-15 |
2009-10-23 |
노파르티스 아게 |
Ｌｂｈ589와 암을 치료하기 위한 다른 치료제와의 조합물
|
|
AU2008335809A1
(en)
*
|
2007-12-06 |
2009-06-18 |
Durect Corporation |
Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
|
|
WO2009118292A1
(en)
|
2008-03-24 |
2009-10-01 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
|
EA019033B1
(ru)
|
2008-03-26 |
2013-12-30 |
Новартис Аг |
Ингибиторы дезацетилазы в, основанные на гидроксамате
|
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
|
EP2370076B1
(en)
*
|
2008-11-28 |
2017-01-04 |
Novartis AG |
Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
|
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
PT2391366E
(pt)
|
2009-01-29 |
2013-02-05 |
Novartis Ag |
Benzimidazoles substituídos para o tratamento de astrocitomas
|
|
GEP20156250B
(en)
|
2009-06-26 |
2015-02-25 |
Novartis Ag |
1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EP2464649A1
(en)
|
2009-08-12 |
2012-06-20 |
Novartis AG |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
|
CA2771432A1
(en)
|
2009-08-20 |
2011-02-24 |
Novartis Ag |
Heterocyclic oxime compounds
|
|
EA201200321A1
(ru)
|
2009-08-26 |
2012-09-28 |
Новартис Аг |
Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
|
|
MX2012002997A
(es)
|
2009-09-10 |
2012-08-01 |
Novartis Ag |
Derivados de eter de los heteroarilos biciclicos.
|
|
PE20121471A1
(es)
|
2009-11-04 |
2012-11-01 |
Novartis Ag |
Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
|
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
|
PE20121384A1
(es)
|
2009-12-08 |
2012-10-13 |
Novartis Ag |
Derivados de sulfonamida heterociclicos
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
|
KR101731008B1
(ko)
|
2010-06-16 |
2017-04-27 |
앙도르쉐르슈 인코포레이티드 |
에스트로겐-관련 질병의 치료 또는 예방 방법
|
|
JP2013532149A
(ja)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
|
|
EP2582680A1
(en)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
EP2627648A1
(en)
|
2010-09-16 |
2013-08-21 |
Novartis AG |
17aHYDROXYLASE/C17,20-LYASE INHIBITORS
|
|
JP2014505088A
(ja)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
|
|
US20130338152A1
(en)
|
2011-03-08 |
2013-12-19 |
Irm Llc |
Fluorophenyl bicyclic heteroaryl compounds
|
|
ES2656218T3
(es)
|
2011-04-28 |
2018-02-26 |
Novartis Ag |
Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa
|
|
PL2709991T3
(pl)
|
2011-05-16 |
2021-04-06 |
Genzyme Corporation |
Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii
|
|
EA201391820A1
(ru)
|
2011-06-09 |
2014-12-30 |
Новартис Аг |
Гетероциклические сульфонамидные производные
|
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
|
WO2012175520A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
|
MX2013015001A
(es)
|
2011-06-27 |
2014-03-31 |
Novartis Ag |
Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
|
|
UY34329A
(es)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
Compuestos de triazolopiridina
|
|
JP5992054B2
(ja)
|
2011-11-29 |
2016-09-14 |
ノバルティス アーゲー |
ピラゾロピロリジン化合物
|
|
IN2014CN04174A
(da)
|
2011-12-22 |
2015-09-04 |
Novartis Ag |
|
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
|
MX2014007729A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
|
BR112014015322A2
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos e composições para inibir a interação de bcl2 com parceiros de ligação
|
|
BR112014015339A2
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos para inibição da interação de bcl2 com parceiros de ligação
|
|
JP2015503517A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
|
|
JP2015503516A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
|
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
|
US20130310387A1
(en)
|
2012-05-16 |
2013-11-21 |
Novartis Ag |
Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
|
|
WO2013175417A1
(en)
|
2012-05-24 |
2013-11-28 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
|
BR112014031421A2
(pt)
|
2012-06-15 |
2017-06-27 |
Brigham & Womens Hospital Inc |
composições para tratamento de câncer e métodos para produção das mesmas
|
|
BR112015003058A2
(pt)
|
2012-08-13 |
2017-07-04 |
Novartis Ag |
derivados bicíclicos de heteroaril cicloalquildiamina como inibidores de tirosina quinases do baço (syk)
|
|
PL2903968T3
(pl)
|
2012-10-02 |
2017-05-31 |
Gilead Sciences, Inc. |
Inhibitory demetylaz histonowych
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
EP2948451B1
(en)
|
2013-01-22 |
2017-07-12 |
Novartis AG |
Substituted purinone compounds
|
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
JP6514117B2
(ja)
|
2013-02-27 |
2019-05-15 |
エピセラピューティクス アーペーエス |
ヒストン脱メチル化酵素の阻害剤
|
|
TW201521769A
(zh)
|
2013-03-15 |
2015-06-16 |
Durect Corp |
具有流變改質劑以減少溶解變異性之組成物
|
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
SG11201600707QA
(en)
|
2013-09-22 |
2016-02-26 |
Calitor Sciences Llc |
Substituted aminopyrimidine compounds and methods of use
|
|
MX2016009226A
(es)
|
2014-01-15 |
2016-10-05 |
Novartis Ag |
Combinaciones farmaceuticas.
|
|
JP6517319B2
(ja)
|
2014-03-28 |
2019-05-22 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ |
置換されたヘテロアリール化合物および使用方法
|
|
EP3126345A1
(en)
|
2014-03-31 |
2017-02-08 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
|
AU2015241198A1
(en)
|
2014-04-03 |
2016-11-17 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
|
KR20170040805A
(ko)
|
2014-08-27 |
2017-04-13 |
길리애드 사이언시즈, 인코포레이티드 |
히스톤 데메틸라제를 억제하기 위한 화합물 및 방법
|
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
|
WO2019119486A1
(zh)
|
2017-12-21 |
2019-06-27 |
中国科学院合肥物质科学研究院 |
一类嘧啶类衍生物激酶抑制剂
|
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
CA3155594A1
(en)
*
|
2019-09-26 |
2021-04-01 |
S.I.S. Shulov Innovative Science Ltd. |
Topical anti-aging compositions comprising a tetrapeptide
|
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
BR112022013784A2
(pt)
|
2020-01-13 |
2022-10-11 |
Durect Corp |
Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
|